FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to Clinic

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Turn-Biotech-FDA

More Like This

PR Newswire associated0

Turn Biotechnologies Announces Landmark Study to Assess Effectiveness of ERA™ Therapy in Restoring Bone Marrow

PR Newswire associated0

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

PR Newswire associated0

Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, With No Distribution to Other Organs

PR Newswire associated0

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

PR Newswire associated0

Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for its Epigenetic Reprogramming Therapies

Rejuveron Life Sciences AG Rebrands as Centenara Labs AG and Provides Latest Clinical Updates

PR Newswire associated0

Seragon Completes Pre-Clinical Study of Aging Intervention Candidate SRN-901

PR Newswire associated0

LifeSpan Vision Ventures Makes 7th Investment in Pursuit of Longevity Mission